Whole-Genome Sequence Analysis of Candida glabrata Isolates from a Patient with Persistent Fungemia and Determination of the Molecular Mechanisms of Multidrug Resistance
暂无分享,去创建一个
Y. Choi | H. Choi | Mina Kim | E. Won | Joo-Heon Park | Jong-Hee Shin | S. Kim | M. Shin | Seung-Jung Kee | H. Choi | Seung Yeob Lee | S. A. Byun | Min Ji Choi | H. Lim | H. Choi | Jong‐Hee Shin
[1] Yong Jun Kwon,et al. Dynamics and Predictors of Mortality Due to Candidemia Caused by Different Candida Species: Comparison of Intensive Care Unit-Associated Candidemia (ICUAC) and Non-ICUAC , 2021, Journal of fungi.
[2] V. S. Parmar,et al. Antimycotic Drugs and their Mechanisms of Resistance to Candida Species. , 2021, Current drug targets.
[3] Mina Kim,et al. Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018 , 2021, Emerging infectious diseases.
[4] T. Gabaldón,et al. The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens , 2020, Journal of fungi.
[5] K. Cronin,et al. Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance , 2020, Antimicrobial Agents and Chemotherapy.
[6] W. S. Moye-Rowley,et al. Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata , 2019, mBio.
[7] M. Kostrzewa,et al. Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1 , 2019, Antimicrobial Agents and Chemotherapy.
[8] Ronald N. Jones,et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.
[9] C. Fairhead,et al. Genome Comparisons of Candida glabrata Serial Clinical Isolates Reveal Patterns of Genetic Variation in Infecting Clonal Populations , 2019, Front. Microbiol..
[10] Yong Jun Kwon,et al. Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping , 2019, Journal of Clinical Microbiology.
[11] Luis V. Santana-Quintero,et al. In‐depth comparative analysis of Illumina® MiSeq run metrics: Development of a wet‐lab quality assessment tool , 2019, Molecular ecology resources.
[12] Erika Shor,et al. Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata , 2019, Emerging microbes & infections.
[13] S. Kelly,et al. ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait , 2018, Antimicrobial Agents and Chemotherapy.
[14] P. Escribano,et al. Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata. , 2018, Medical mycology.
[15] Mina Kim,et al. Multilocus Sequence Typing (MLST) Genotypes of Candida glabrata Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes , 2018, Front. Microbiol..
[16] D. Marriott,et al. Whole Genome Sequencing of Australian Candida glabrata Isolates Reveals Genetic Diversity and Novel Sequence Types , 2018, Front. Microbiol..
[17] P. Escribano,et al. Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates , 2018, Antimicrobial Agents and Chemotherapy.
[18] C. Fairhead,et al. Patterns of Genomic Variation in the Opportunistic Pathogen Candida glabrata Suggest the Existence of Mating and a Secondary Association with Humans , 2018, Current Biology.
[19] P. Le Pape,et al. Molecular basis of antifungal drug resistance in yeasts. , 2017, International journal of antimicrobial agents.
[20] S. Suh,et al. Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: Comparison between respiratory and ear isolates , 2017, PloS one.
[21] M. Arendrup,et al. Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment , 2017, The Journal of infectious diseases.
[22] S. Bates,et al. Galleria mellonella as a host model to study Candida glabrata virulence and antifungal efficacy , 2017, Virulence.
[23] Christina A. Cuomo,et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] Marek S. Skrzypek,et al. The Candida Genome Database (CGD): incorporation of Assembly 22, systematic identifiers and visualization of high throughput sequencing data , 2016, Nucleic Acids Res..
[25] B. Alexander,et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance , 2016, Nature Communications.
[26] C. Clancy,et al. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection , 2015, Antimicrobial Agents and Chemotherapy.
[27] M. Arendrup,et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. , 2015, The Journal of antimicrobial chemotherapy.
[28] H. Sung,et al. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia. , 2014, The Journal of antimicrobial chemotherapy.
[29] D. Kontoyiannis,et al. Drug-Resistant Candida glabrata Infection in Cancer Patients , 2014, Emerging infectious diseases.
[30] W. Schaffner,et al. Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance , 2014, Antimicrobial Agents and Chemotherapy.
[31] E. Mellado,et al. Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella , 2014, Virulence.
[32] F. Queiroz-Telles,et al. Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin , 2014, Antimicrobial Agents and Chemotherapy.
[33] S. Andreoni,et al. Antifungal resistance does not necessarily affect Candida glabrata fitness , 2014, Journal of chemotherapy.
[34] M. Henriques,et al. Candida glabrata: a review of its features and resistance , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[35] Ronald N. Jones,et al. Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates , 2013, Antimicrobial Agents and Chemotherapy.
[36] M. Castanheira,et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] D. Kelly,et al. Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in ERG2 , 2012, Antimicrobial Agents and Chemotherapy.
[38] J. Heitman,et al. Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata , 2012, PLoS pathogens.
[39] Jong-Hee Shin,et al. First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris , 2011, Journal of Clinical Microbiology.
[40] M. Arendrup. Epidemiology of invasive candidiasis , 2010, Current opinion in critical care.
[41] D. Kelly,et al. Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.
[42] D. Kelly,et al. A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B , 2010, Antimicrobial Agents and Chemotherapy.
[43] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[44] C. Hennequin,et al. Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.
[45] B. Dujon,et al. Genomic polymorphism in the population of Candida glabrata: gene copy-number variation and chromosomal translocations. , 2009, Fungal genetics and biology : FG & B.
[46] J. Bouchara,et al. A Nonsense Mutation in the ERG6 Gene Leads to Reduced Susceptibility to Polyenes in a Clinical Isolate of Candida glabrata , 2008, Antimicrobial Agents and Chemotherapy.
[47] K. Marr. Fungal infections in hematopoietic stem cell transplant recipients. , 2008, Medical mycology.
[48] C. Hennequin,et al. Reduced Susceptibility to Polyenes Associated with a Missense Mutation in the ERG6 Gene in a Clinical Isolate of Candida glabrata with Pseudohyphal Growth , 2006, Antimicrobial Agents and Chemotherapy.
[49] M. Falagas,et al. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[50] M. Arendrup,et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] S. A. Parent,et al. Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[52] M. Maiden,et al. Optimization and Validation of Multilocus Sequence Typing for Candida albicans , 2003, Journal of Clinical Microbiology.
[53] D. Sanglard,et al. Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.
[54] S. Kohlwein,et al. Biochemical characterization and subcellular localization of the sterol C‐24(28) reductase, Erg4p, from the yeast Saccharomyces cerevisiae , 2000, FEBS letters.
[55] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[56] D. Kelly,et al. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients , 1996, The Lancet.
[57] J. Swartz,et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.
[58] Sudhir Kumar,et al. MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers , 1994, Comput. Appl. Biosci..